Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Interest & Investment Income (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Interest & Investment Income data on record, last reported at $2.7 million in Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 5.05% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $11.8 million, up 14.6%, while the annual FY2024 figure was $10.6 million, 13.2% up from the prior year.
  • Interest & Investment Income reached $2.7 million in Q3 2025 per GLUE's latest filing, down from $3.1 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.4 million in Q1 2025 and bottomed at $2.2 million in Q3 2023.
  • Average Interest & Investment Income over 3 years is $2.7 million, with a median of $2.6 million recorded in 2024.
  • The widest YoY moves for Interest & Investment Income: up 40.83% in 2025, down 5.05% in 2025.
  • A 3-year view of Interest & Investment Income shows it stood at $2.4 million in 2023, then grew by 9.59% to $2.6 million in 2024, then rose by 5.82% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $2.7 million in Q3 2025, $3.1 million in Q2 2025, and $3.4 million in Q1 2025.